Login to Your Account



Pierre Fabre lands ex-U.S. rights to Array's Mek-BRAF combo in $455M deal

By Cormac Sheridan
Staff Writer

Monday, November 16, 2015

DUBLIN – Pierre Fabre SA is paying Array Biopharma Inc. $30 million up front plus up to $425 million more in milestones for European, Asian and Latin American rights to binimetinib and encorafenib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription